You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 8, 2024

Iloprost - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for iloprost and what is the scope of freedom to operate?

Iloprost is the generic ingredient in two branded drugs marketed by Actelion and Eicos Sci, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for iloprost. Two suppliers are listed for this compound.

Summary for iloprost

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	59
Clinical Trials:	98
Patent Applications:	7,223
Formulation / Manufacturing:	see details
What excipients (inactive ingredients) are in iloprost?	iloprost excipients list
DailyMed Link:	iloprost at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for iloprost

Generic Entry Date for iloprost^: ⤷ Try a Trial* Constraining patent/regulatory exclusivity: TREATMENT OF SEVERE FROSTBITE IN ADULTS TO REDUCE THE RISK OF DIGIT AMPUTATIONS Dosage: SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for iloprost

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
DiaMed GmbH	N/A
Peter Korsten	N/A
Charite University, Berlin, Germany	Phase 1/Phase 2

See all iloprost clinical trials

Pharmacology for iloprost

Drug Class	Prostacycline

Medical Subject Heading (MeSH) Categories for iloprost

Platelet Aggregation Inhibitors
Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for iloprost

B01AC	Platelet aggregation inhibitors excl. heparin
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

US Patents and Regulatory Information for iloprost

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion	VENTAVIS	iloprost	SOLUTION;INHALATION	021779-003	Aug 7, 2009		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Eicos Sci	AURLUMYN	iloprost	SOLUTION;INTRAVENOUS	217933-001	Feb 13, 2024		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Eicos Sci	AURLUMYN	iloprost	SOLUTION;INTRAVENOUS	217933-001	Feb 13, 2024		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Actelion	VENTAVIS	iloprost	SOLUTION;INHALATION	021779-002	Dec 8, 2005		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

EU/EMA Drug Approvals for iloprost

Subscribe to access the full database, or Try a Trial
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bayer AG	Ventavis	iloprost	EMEA/H/C/000474 Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms.	Authorised	no	no	no	2003-09-15
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.